Latest / Cleveland Clinic Cancer Advances
Unlocking the Impact of ESR1 Mutations and PI3K Pathway on Elacestrant in Advanced Breast Cancer
Ali Azka, MD, medical oncologist specializing in breast cancer joins the Cancer Advances podcast to talk about her new research on ESR1 mutations and the PI3-kinase pathway's impact on the effectiveness of elacestrant in treating advanced hormone receptor-positive, HER2-negative breast cancer. This study, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), highlights the role of real-world data, optimal treatment sequencing, and the evolving landscape of targeted therapies. Tune in as Dr. Azka explores these advancements and their potential to improve patient outcomes.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.